Show simple item record

dc.contributor.authorPettengell, Ruthen
dc.contributor.authorTesta, Nydia Gen
dc.date.accessioned2010-05-20T15:23:52Z
dc.date.available2010-05-20T15:23:52Z
dc.date.issued1995-01
dc.identifier.citationBiology of blood progenitor cells used in transplantation. 1995, 61 (1):1-15 Int. J. Hematol.en
dc.identifier.issn0925-5710
dc.identifier.pmid7718764
dc.identifier.urihttp://hdl.handle.net/10541/99444
dc.description.abstractBlood progenitor cells (BPC) are increasingly used in a variety of clinical settings. These include autologous and allogeneic transplantation after myeloablative therapy, and gene therapy. The optimal blood products for each of these applications have not been defined. The use of different cytotoxic drugs and cytokines, alone and in combination, results in the mobilisation of different total numbers and relative proportions of primitive and committed BPC. Some cytotoxics and cytokines not only are poor at mobilising BPC, but also are myelotoxic. Here we review the biology of BPC mobilisation and its implications for their clinical use.
dc.language.isoenen
dc.subjectHaematopoietic Stem Cell Transplantationen
dc.subject.meshAntineoplastic Agents
dc.subject.meshCytokines
dc.subject.meshHematopoietic Stem Cell Transplantation
dc.subject.meshHumans
dc.titleBiology of blood progenitor cells used in transplantation.en
dc.typeArticleen
dc.contributor.departmentCRC Department of Medical Oncology, Christie Hospital, Manchester, UK.en
dc.identifier.journalInternational Journal of Hematologyen
html.description.abstractBlood progenitor cells (BPC) are increasingly used in a variety of clinical settings. These include autologous and allogeneic transplantation after myeloablative therapy, and gene therapy. The optimal blood products for each of these applications have not been defined. The use of different cytotoxic drugs and cytokines, alone and in combination, results in the mobilisation of different total numbers and relative proportions of primitive and committed BPC. Some cytotoxics and cytokines not only are poor at mobilising BPC, but also are myelotoxic. Here we review the biology of BPC mobilisation and its implications for their clinical use.


This item appears in the following Collection(s)

Show simple item record